Clinuvel Pharmaceuticals (CUV)
Clinuvel Pharmaceuticals Ltd. operates as a global biopharmaceutical company, which is focused on the development of SCENESSE, its proprietary photoprotective drug. It also focuses on developing drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
|Market Price at 20-11-2017||$8.95|
|Price to Earnings Ratio||45.62|
|Market Capitalisation||$418.64 (million)|
|Return on Equity (ROE)||28.29%|